

VIVA Company News

Viva Biotech Awarded Successively “Top 20 Chinese R&D Enterprises in 2022” and Langhua Awarded “Top 20 Chinese CDMO Enterprises in 2022”

On December 9, the "2022 High-Quality Development Conference of the Great Health Industry and the 7th China Pharmaceutical R&D and Innovation Summit" was held online. The conference, co-organized by YAOZH.COM and China Pharmaceuticals Magazine, featured the publication of the "2022 China Pharmaceutical Industry R&D Strength Ranking Series List". As a world-leading one-stop platform for drug R&D and production services, Viva Biotech was awarded "Top 20 Chinese R&D CRO Enterprises in 2022" and placed sixth on the list. Additionally, Viva's subsidiary, Langhua Pharmaceutical, was recognized as one of the "Top 20 Chinese CDMO Enterprises in 2022".

Viva Biotech and its subsidiary Langhua Pharmaceutical have been recognized for their comprehensive strength in the pharmaceutical industry, winning two awards in a row at the "2022 High-Quality Development Conference of the Great Health Industry and the 7th China Pharmaceutical R&D and Innovation Summit". Viva Biotech is a one-stop platform for drug development, providing global innovative drug R&D companies with comprehensive services from SBDD to commercial drug delivery. This year, the company successfully completed the construction of its new headquarters for the integration of drug R&D. By building advanced technology platforms, a first-class R&D team, and complete operating facilities, Viva Biotech aims to create more comprehensive services throughout the industry chain, empowering the innovation and development of biomedicine. The company continues to expand its team of scientific talent and scale its operations, with more than 2,300 employees worldwide and R&D centers in multiple cities in China and branches in 10 countries to quickly respond to global market needs.



VIVA Company News

Completion Ceremony of Viva Biotech's Headquarters

On November 10, the inauguration ceremony of Viva Biotech's headquarters took place in Zhoupu, Pudong New Area, Shanghai. The people in attendance included: Mr. Qiang Wu, Deputy District Mayor of Shanghai Pudong New Area; Mr. Gang Ling, Chief Engineer of Shanghai Pudong Technical and Economy Committee ; Mr. Kairong Wang, Deputy General Manager of Shanghai Zhangjiang (Group) Co., Ltd.; Mr. Jianping Wu, General Manager of Shanghai Free Trade Zone Fund; Ms. Jiayao Xuan, Deputy General Manager of Shanghai Zhangjiang Technology Venture Capital Co., Ltd.; Ms. Tian Shen, Mayor of Youchegang Town, Xiuzhou District, Jiaxing City; Mr. Weidong Yu, Chairman of Jiaxing Linhu Holding Group Co., Ltd. More than 100 guests, including entrepreneurs, scientists, and investment institutions attended the event to witness the important milestone. Mr. Qiang Wu, Deputy District Mayor of Shanghai Pudong New Area, began the ceremony with a speech, and Dr. Cheney Mao, Chairman and CEO of Viva Biotech, expressed his gratitude to all the leaders and guests.

The completion of Viva Biotech's headquarters is an integral part of its expansion and strategy, and it has enhanced the company's comprehensive R&D capabilities. Going forward, Viva will continue to rely on its unique advantages in structure-based drug development (SBDD) to build and continuously improve technical barriers, improve efficiency, strengthen the one-stop drug R&D and production service platform, and deepen the relationship between the CRO and CDMO business. Viva strives for synergy and actively builds an open cooperation platform and a win-win ecosystem for global biomedical innovators.



Mr. Qiang Wu
Deputy District Mayor of Shanghai Pudong New Area



Dr. Cheney Mao
Chairman and CEO of Viva Biotech



Guests Visit the Laboratories

Material Deal



Focus-X Therapeutics Successfully Reached an Acquisition Agreement with Full-Life Technologies

Nov. 29, 2022, Focus-X Therapeutics (referred to here as "Focus-X") successfully reached an acquisition agreement with Full-Life Technologies Co., Ltd. (referred to here as "Full-Life"). Under the terms of the acquisition, Full-Life will acquire Focus-X for US\$245 million, including an upfront payment, potential development, regulatory, and sales-based milestone fees, and royalties on commercial sales. The acquisition is expected to close in the first quarter of 2023. When finished, this will be another pre-clinical acquisition of one of Viva's portfolio companies, after Dogma and Totient, which once again verifies the capabilities of project discovery and the professional post-investment support of Viva's investment team.

Research & Development Progress



QureBio Ltd. to Present its Q-1802 Clinical Phase I Data at 2023 ASCO-GI Meetings

On Dec. 21, 2022, QureBio Ltd. announced that Phase I Clinical Data of its Q-1802 program will be presented at ASCO Gastrointestinal Cancers Symposium (ASCO-GI) hold at the San Francisco and online on January 19–21, 2023. The abstract will be found in 2023 ASCO Gastrointestinal Cancers Symposium–Meeting Abstracts (#382).

Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsAbs in patients with relapsed or refractory solid tumors

- Q-1802 is a humanized bispecific antibody
- targets both the tumor -specific antigen CLDN18.2 and the immune checkpoint PD-L1
- Q-1802 has excellent safety, tolerability
- Q-1802 has excellent anti-tumor activity in CLDN18.2 positive GI patients

Q-1802, a humanized bispecific antibody, is the first FDA-approved and the first enter clinical trial Claudin18.2/PD-L1 bispecific antibody, as well as the first to present clinical data at ASCO annual meeting. It recruits multiple immune mechanisms to kill tumor cells, offering a novel therapeutic opportunity for Claudin18.2 positive solid tumors. Q-1802 exhibits high affinity and selectivity, and patients with low or high expression of CLDN18.2 can benefit from it. The current clinical phase I data verify both superior anti-tumor activities and excellent safety profiles. The molecular design of Q-1802 is rational and effective, the production process is robust with high yield.

Research & Development Progress

BioCasting and Corning Life Sciences Build an in Vitro 3D Model of CAR-NK Cells Infiltrating a Tumor's Extracellular Matrix to Help Target and Kill Tumor Cells



On November 22th, BioCasting announced jointly with Corning Life Sciences, and Olympus Microscopy the establishment of the "BioCasting Phenotypic Screening Platform Based on the Complex Disease Modeling and Bioimaging." All three companies will work together to build up a platform. The screening platform will integrate BioCasting's complex disease modeling technology platform, Corning Life Sciences' high-quality biotechnology products, and global experience, and the excellent biological imaging solutions of Olympus Microscopy's to provide customers with the highest quality drug screening services.

Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001



Aleta Biotherapeutics (Aleta) announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) for Chimeric Antigen Receptor (CAR) T-cell therapy Engager candidate ALETA-001 for the treatment of patients suffering from the B-cell malignancies, non-Hodgkin lymphoma (NHL) and Acute Lymphoblastic Leukemia (ALL), and who have failed to respond or have relapsed post-CD19 CAR T-cell therapy. ALETA-001 is expected to enter clinical development in 2023 with Cancer Research UK's Centre for Drug Development sponsoring and conducting a Phase 1/2a clinical trial.

Business Progress

Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12



November 01, 2022, Exelixis, Inc. and Cybrexa Therapeutics (Cybrexa), invested and incubated by Viva BioInnovator, announced that the companies have entered into an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12 (alphalex exatecan), a clinical-stage, first-in-class peptide-drug conjugate (PDC) that utilizes Cybrexa's proprietary alphalex technology to enhance delivery of exatecan to tumor cells. CBX-12 is designed to increase the efficacy and reduce the toxicity of topoisomerase I inhibition by delivering exatecan, a highly potent, second-generation topoisomerase I inhibitor, directly to the tumor cells. This collaboration underscores Exelixis' commitment to expanding its clinical pipeline building upon its biotherapeutics and targeted drug therapy expertise.

Business Progress



AlxplorerBio Won the "HCH Ventures Top Ten Overseas Talent Entrepreneurship Project"

On November 28, AlxplorerBio, invested and incubated by Viva BioInnovator, was invited to participate in the 2022 Pudong New Area Innovation and Entrepreneurship Summit. Standing out from 300+ outstanding projects, AlxplorerBio won the "HCH Ventures Top Ten Overseas Talent Entrepreneurship Project." HCH2022 was co-hosted by Shanghai Association for Science & Tech, Pudong Technical and Economy Committee, and Zhangjiang Hi-tech Park Administrative Committee. AlxplorerBio continues to gather resources and talent advantages in the field of biomedicine and artificial intelligence in Pudong New Area and strives to accelerate the development of innovative drug R&D projects by introducing professional talents.



DTx Pharma and HAYA Therapeutics are included in Clarivate's New "RNA Technology Companies to Watch" Report

October 25, 2022: Clarivate Plc (NYSE:CLVT) announced the release of a new report called "RNA Technology Companies to Watch." The report comprehensively analyzes RNA companies' drug benefits, financing, and R&D activities to reveal emerging outstanding RNA companies in the medical field. Clarivate identifies seven innovators in the report, including DTx Pharma and HAYA Therapeutics, which are invested in and incubated by Viva BioInnovator. In addition, on November 13, Haya Therapeutics was awarded the "Seed-Stage Finance Raise of the Year" award at the European Lifestars Awards held by LSX.



About Viva Biotech

Listing Date

2019.05.09

Price (2023.01.17)

HKD 2.02

52 WK Range

HKD 1.16-4.68

Market Cap (2023.01.17)

HKD 3.909B

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, ASMS, SPR, HDX, CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

As of June 30, 2022, Viva Biotech has provided drug R&D and production services to 1,947 biotech and pharmaceutical clients around the world. We have invested and incubated 90 biotech start-ups in total. In the future, the Company will continue to strengthen its technical barriers and improve R&D, production levels, and our service capacity to provide high-quality and diversified services for more drug discovery start-ups, as well as medium and large pharmaceutical enterprises around the world.

Investor & Media Enquiries

Viva Biotech Holdings website: www.vivabiotech.com

For further information, please contact: Tel: 852-3150 6788

Email: ir@vivabiotech.com; VivaBiotech.hk@pordahavas.com